mouse breast cancer cell line py230 Search Results


py230  (ATCC)
95
ATCC py230
Representative IHC images of tumor area in (A) B16-F10-Luc2 lung tumors, (B) <t>Py230</t> breast tumor, (C) LLC-Luc2 lung tumors, (D) 4T1-Luc2 lung tumors, and (E) 13762 lung tumors. AnxA1 expression (brown) was seen in endothelial cells lining microvessels (yellow arrows) in the B16-F10-Luc2 lung metastatic tumor model and the Py230 tumor model, but not in the LLC-Luc2 lung metastatic tumor model, the 4T1-Luc2 lung metastatic tumor model, or the 13762 rat lung metastatic tumor model, despite 1–3+ staining in metastatic neoplastic cells. Note that in B, C, D, and E, there is strong anxA1 expression in macrophages (red arrows). All scale bars = 10 μm.
Py230, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+py230/pmc07272081-63-35-38?v=ATCC
Average 95 stars, based on 1 article reviews
py230 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
mouse triple negative breast cancer cells py230  (ATCC)
95
ATCC mouse triple negative breast cancer cells py230
Figure 1. ADMA inhibits the phagocytic uptake of tumor antigens. The histograms illustrate the mean fluorescence intensity per dendritic cell analyzed by flow cytometry. Phagocytosis in DC2.4 cells was assessed using two types of pHrodo-labeled tumor antigens: EO771-derived tumor proteins (A) and <t>Py230-derived</t> tumor antigens (B), with bacterial antigens serving as a positive control. Data are pooled from at least three independent experiments and presented as mean ± SD. (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
Mouse Triple Negative Breast Cancer Cells Py230, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+py230/pm40429627-333-10-17?v=ATCC
Average 95 stars, based on 1 article reviews
mouse triple negative breast cancer cells py230 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


Representative IHC images of tumor area in (A) B16-F10-Luc2 lung tumors, (B) Py230 breast tumor, (C) LLC-Luc2 lung tumors, (D) 4T1-Luc2 lung tumors, and (E) 13762 lung tumors. AnxA1 expression (brown) was seen in endothelial cells lining microvessels (yellow arrows) in the B16-F10-Luc2 lung metastatic tumor model and the Py230 tumor model, but not in the LLC-Luc2 lung metastatic tumor model, the 4T1-Luc2 lung metastatic tumor model, or the 13762 rat lung metastatic tumor model, despite 1–3+ staining in metastatic neoplastic cells. Note that in B, C, D, and E, there is strong anxA1 expression in macrophages (red arrows). All scale bars = 10 μm.

Journal: PLoS ONE

Article Title: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models

doi: 10.1371/journal.pone.0234268

Figure Lengend Snippet: Representative IHC images of tumor area in (A) B16-F10-Luc2 lung tumors, (B) Py230 breast tumor, (C) LLC-Luc2 lung tumors, (D) 4T1-Luc2 lung tumors, and (E) 13762 lung tumors. AnxA1 expression (brown) was seen in endothelial cells lining microvessels (yellow arrows) in the B16-F10-Luc2 lung metastatic tumor model and the Py230 tumor model, but not in the LLC-Luc2 lung metastatic tumor model, the 4T1-Luc2 lung metastatic tumor model, or the 13762 rat lung metastatic tumor model, despite 1–3+ staining in metastatic neoplastic cells. Note that in B, C, D, and E, there is strong anxA1 expression in macrophages (red arrows). All scale bars = 10 μm.

Article Snippet: The mouse melanoma cancer cell line B16-F10-Luc2 (catalog number ATCC CRL-6475-LUC2), the Lewis lung carcinoma (LLC) cell line LL/2-Luc2 (catalog number ATCC CRL-1642-LUC2), the mouse mammary cancer cell lines 4T1-Luc2 (catalog number ATCC CRL-2539-LUC2) and Py230 (catalog number ATCC CRL-3279), and the rat mammary adenocarcinoma cell line 13762 (catalog number ATCC CRL-1666) were obtained from American Type Culture Collection (ATCC) (Rockville, MD).

Techniques: Expressing, Staining

Immunohistochemical expression of anxA1 (brown) in Py230 tumors at (A) day 25, (B) day 30, (C) day 35, and (D) day 44. Microvascular endothelial cell expression of anxA1 (yellow arrows) begins at day 30 and increases in extent and intensity through day 44. Note that macrophages also exhibit strong anxA1 expression (red arrows). All scale bars = 10 μm.

Journal: PLoS ONE

Article Title: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models

doi: 10.1371/journal.pone.0234268

Figure Lengend Snippet: Immunohistochemical expression of anxA1 (brown) in Py230 tumors at (A) day 25, (B) day 30, (C) day 35, and (D) day 44. Microvascular endothelial cell expression of anxA1 (yellow arrows) begins at day 30 and increases in extent and intensity through day 44. Note that macrophages also exhibit strong anxA1 expression (red arrows). All scale bars = 10 μm.

Article Snippet: The mouse melanoma cancer cell line B16-F10-Luc2 (catalog number ATCC CRL-6475-LUC2), the Lewis lung carcinoma (LLC) cell line LL/2-Luc2 (catalog number ATCC CRL-1642-LUC2), the mouse mammary cancer cell lines 4T1-Luc2 (catalog number ATCC CRL-2539-LUC2) and Py230 (catalog number ATCC CRL-3279), and the rat mammary adenocarcinoma cell line 13762 (catalog number ATCC CRL-1666) were obtained from American Type Culture Collection (ATCC) (Rockville, MD).

Techniques: Immunohistochemical staining, Expressing

Figure 1. ADMA inhibits the phagocytic uptake of tumor antigens. The histograms illustrate the mean fluorescence intensity per dendritic cell analyzed by flow cytometry. Phagocytosis in DC2.4 cells was assessed using two types of pHrodo-labeled tumor antigens: EO771-derived tumor proteins (A) and Py230-derived tumor antigens (B), with bacterial antigens serving as a positive control. Data are pooled from at least three independent experiments and presented as mean ± SD. (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Journal: International journal of molecular sciences

Article Title: Asymmetric Dimethylarginine Disrupts Tumor Antigen Presentation in Breast Cancer.

doi: 10.3390/ijms26104482

Figure Lengend Snippet: Figure 1. ADMA inhibits the phagocytic uptake of tumor antigens. The histograms illustrate the mean fluorescence intensity per dendritic cell analyzed by flow cytometry. Phagocytosis in DC2.4 cells was assessed using two types of pHrodo-labeled tumor antigens: EO771-derived tumor proteins (A) and Py230-derived tumor antigens (B), with bacterial antigens serving as a positive control. Data are pooled from at least three independent experiments and presented as mean ± SD. (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Article Snippet: Mouse dendritic cells (DC2.4; SCC142, Sigma-Aldrich, St. Louis, MO, USA), mouse triple-negative breast cancer cells Py230 (CRL-3297TM, ATCC, Manassas, VA, USA), and mouse breast cancer cells EO771 (CRL-3461TM, ATCC), which have been variably classified as either luminal B [49] or triple-negative breast cancer [50] in the literature, were cultured in complete RPMI 1640 medium (Cat. #10-040-CV, Corning, Corning, NY, USA) supplemented with 10% fetal bovine serum (FBS; 10082-147, ThermoFisher Scientific, Waltham, MA, USA) and 1% penicillin–streptomycin (SV30010, Cytiva, Marlborough, MA, USA).

Techniques: Fluorescence, Flow Cytometry, Labeling, Derivative Assay, Positive Control

Figure 4. ADMA inhibits tumor antigen presentation on the surface of dendritic cells. DC2.4 cells were exposed to DBCO-labeled tumor antigens in the presence or absence of ADMA for six days, followed by flow cytometry analysis. The histograms compare the mean fluorescence intensity across groups based on flow cytometry data. To assess the impact of ADMA on antigen presentation, two types of DBCO-labeled tumor proteins were used: EO771-derived tumor proteins (A) and Py230- derived tumor proteins (B). Data represent pooled results from at least three independent experiments and are presented as mean ± SD (*, p < 0.05; **, p < 0.01).

Journal: International journal of molecular sciences

Article Title: Asymmetric Dimethylarginine Disrupts Tumor Antigen Presentation in Breast Cancer.

doi: 10.3390/ijms26104482

Figure Lengend Snippet: Figure 4. ADMA inhibits tumor antigen presentation on the surface of dendritic cells. DC2.4 cells were exposed to DBCO-labeled tumor antigens in the presence or absence of ADMA for six days, followed by flow cytometry analysis. The histograms compare the mean fluorescence intensity across groups based on flow cytometry data. To assess the impact of ADMA on antigen presentation, two types of DBCO-labeled tumor proteins were used: EO771-derived tumor proteins (A) and Py230- derived tumor proteins (B). Data represent pooled results from at least three independent experiments and are presented as mean ± SD (*, p < 0.05; **, p < 0.01).

Article Snippet: Mouse dendritic cells (DC2.4; SCC142, Sigma-Aldrich, St. Louis, MO, USA), mouse triple-negative breast cancer cells Py230 (CRL-3297TM, ATCC, Manassas, VA, USA), and mouse breast cancer cells EO771 (CRL-3461TM, ATCC), which have been variably classified as either luminal B [49] or triple-negative breast cancer [50] in the literature, were cultured in complete RPMI 1640 medium (Cat. #10-040-CV, Corning, Corning, NY, USA) supplemented with 10% fetal bovine serum (FBS; 10082-147, ThermoFisher Scientific, Waltham, MA, USA) and 1% penicillin–streptomycin (SV30010, Cytiva, Marlborough, MA, USA).

Techniques: Immunopeptidomics, Labeling, Flow Cytometry, Fluorescence, Derivative Assay

Figure 5. CD25 expression was selectively altered in splenic CD4+ T cells following antigen presen- tation by ADMA-treated DC2.4 cells. The percentage of CD25-expressing T cells was assessed by flow cytometry. A reduced percentage of CD4+ T cells was observed following antigen presentation by ADMA-treated DC2.4 cells presenting antigens from EO771 (A) and Py230 (C). In contrast, no significant difference was detected in the percentage of CD25-expressing CD8+ T cells after antigen presentation by ADMA-treated DC2.4 cells presenting antigens from EO771 (B) and Py230 (D). Data were pooled from at least three independent experiments and are presented as mean ± SD (*, p < 0.05; **, p < 0.01; ns, no statistical significance).

Journal: International journal of molecular sciences

Article Title: Asymmetric Dimethylarginine Disrupts Tumor Antigen Presentation in Breast Cancer.

doi: 10.3390/ijms26104482

Figure Lengend Snippet: Figure 5. CD25 expression was selectively altered in splenic CD4+ T cells following antigen presen- tation by ADMA-treated DC2.4 cells. The percentage of CD25-expressing T cells was assessed by flow cytometry. A reduced percentage of CD4+ T cells was observed following antigen presentation by ADMA-treated DC2.4 cells presenting antigens from EO771 (A) and Py230 (C). In contrast, no significant difference was detected in the percentage of CD25-expressing CD8+ T cells after antigen presentation by ADMA-treated DC2.4 cells presenting antigens from EO771 (B) and Py230 (D). Data were pooled from at least three independent experiments and are presented as mean ± SD (*, p < 0.05; **, p < 0.01; ns, no statistical significance).

Article Snippet: Mouse dendritic cells (DC2.4; SCC142, Sigma-Aldrich, St. Louis, MO, USA), mouse triple-negative breast cancer cells Py230 (CRL-3297TM, ATCC, Manassas, VA, USA), and mouse breast cancer cells EO771 (CRL-3461TM, ATCC), which have been variably classified as either luminal B [49] or triple-negative breast cancer [50] in the literature, were cultured in complete RPMI 1640 medium (Cat. #10-040-CV, Corning, Corning, NY, USA) supplemented with 10% fetal bovine serum (FBS; 10082-147, ThermoFisher Scientific, Waltham, MA, USA) and 1% penicillin–streptomycin (SV30010, Cytiva, Marlborough, MA, USA).

Techniques: Expressing, Flow Cytometry, Immunopeptidomics

Figure 6. Antigen presentation by ADMA-treated DC2.4 cells modulates cytokine production in T cells. DC2.4 cells were exposed to tumor antigens derived from EO771 (A,C) and Py230 (B,D) cell lines for six days, with or without ADMA treatment. Supernatants were collected to assess cytokine secretion by primed T cells using ELISA, specifically measuring IFN-γ (A,B) and IL-2 (C,D). Data were pooled from at least three independent experiments and are presented as mean ± SD (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Journal: International journal of molecular sciences

Article Title: Asymmetric Dimethylarginine Disrupts Tumor Antigen Presentation in Breast Cancer.

doi: 10.3390/ijms26104482

Figure Lengend Snippet: Figure 6. Antigen presentation by ADMA-treated DC2.4 cells modulates cytokine production in T cells. DC2.4 cells were exposed to tumor antigens derived from EO771 (A,C) and Py230 (B,D) cell lines for six days, with or without ADMA treatment. Supernatants were collected to assess cytokine secretion by primed T cells using ELISA, specifically measuring IFN-γ (A,B) and IL-2 (C,D). Data were pooled from at least three independent experiments and are presented as mean ± SD (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Article Snippet: Mouse dendritic cells (DC2.4; SCC142, Sigma-Aldrich, St. Louis, MO, USA), mouse triple-negative breast cancer cells Py230 (CRL-3297TM, ATCC, Manassas, VA, USA), and mouse breast cancer cells EO771 (CRL-3461TM, ATCC), which have been variably classified as either luminal B [49] or triple-negative breast cancer [50] in the literature, were cultured in complete RPMI 1640 medium (Cat. #10-040-CV, Corning, Corning, NY, USA) supplemented with 10% fetal bovine serum (FBS; 10082-147, ThermoFisher Scientific, Waltham, MA, USA) and 1% penicillin–streptomycin (SV30010, Cytiva, Marlborough, MA, USA).

Techniques: Immunopeptidomics, Derivative Assay, Enzyme-linked Immunosorbent Assay